
Jodi Marie Saunus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4599857/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature, 2015, 527, 100-104.	27.8	966
2	Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. Journal of Pathology, 2015, 237, 363-378.	4.5	98
3	Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications. Journal of Pathology, 2019, 247, 214-227.	4.5	73
4	Blocking immunosuppressive neutrophils deters pY696-EZH2–driven brain metastases. Science Translational Medicine, 2020, 12, .	12.4	64
5	Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget, 2015, 6, 3932-3946.	1.8	60
6	<scp>CEP</scp> 55 is a determinant of cell fate during perturbed mitosis in breast cancer. EMBO Molecular Medicine, 2018, 10, .	6.9	59
7	Long-range regulators of the lncRNA <i>HOTAIR</i> enhance its prognostic potential in breast cancer. Human Molecular Genetics, 2016, 25, 3269-3283.	2.9	58
8	Calcium signalling and breast cancer. Seminars in Cell and Developmental Biology, 2019, 94, 74-83.	5.0	58
9	In Vitro Analysis of Breast Cancer Cell Line Tumourspheres and Primary Human Breast Epithelia Mammospheres Demonstrates Inter- and Intrasphere Heterogeneity. PLoS ONE, 2013, 8, e64388.	2.5	55
10	The calcium pump plasma membrane Ca2+-ATPase 2 (PMCA2) regulates breast cancer cell proliferation and sensitivity to doxorubicin. Scientific Reports, 2016, 6, 25505.	3.3	53
11	Posttranscriptional Regulation of the Breast Cancer Susceptibility Gene BRCA1 by the RNA Binding Protein HuR. Cancer Research, 2008, 68, 9469-9478.	0.9	49
12	ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype. Nature Communications, 2015, 6, 6548.	12.8	49
13	Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer. Oncotarget, 2014, 5, 3145-3158.	1.8	42
14	DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer. Oncogene, 2017, 36, 4802-4809.	5.9	40
15	Cellular and molecular mechanisms of resistance to oral Candida albicans infections. Frontiers in Bioscience - Landmark, 2008, Volume, 5345.	3.0	34
16	Expression of <scp>MAGE</scp> â€A and <scp>NY</scp> â€ <scp>ESO</scp> â€1 cancer/testis antigens is enriched in tripleâ€negative invasive breast cancers. Histopathology, 2018, 73, 68-80.	2.9	34
17	Mixed ductal″obular carcinomas: evidence for progression from ductal to lobular morphology. Journal of Pathology, 2018, 244, 460-468.	4.5	31
18	Breast cancer metastasis to gynaecological organs: a clinicoâ€pathological and molecular profiling study. Journal of Pathology: Clinical Research, 2019, 5, 25-39.	3.0	31

Jodi Marie Saunus

#	Article	IF	CITATIONS
19	LobSig is a multigene predictor of outcome in invasive lobular carcinoma. Npj Breast Cancer, 2019, 5, 18.	5.2	28
20	Multidimensional phenotyping of breast cancer cell lines to guide preclinical research. Breast Cancer Research and Treatment, 2018, 167, 289-301.	2.5	27
21	Breast Cancer Heterogeneity in Primary and Metastatic Disease. Advances in Experimental Medicine and Biology, 2019, 1152, 75-104.	1.6	27
22	Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib. PLoS ONE, 2015, 10, e0125232.	2.5	27
23	Novel highly specific antiâ€periostin antibodies uncover the functional importance of the fascilin 1â€1 domain and highlight preferential expression of periostin in aggressive breast cancer. International Journal of Cancer, 2016, 138, 1959-1970.	5.1	26
24	Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1. British Journal of Cancer, 2020, 123, 1665-1672.	6.4	26
25	SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer. Oncotarget, 2016, 7, 72807-72818.	1.8	26
26	Molecular classification of breast carcinoma. Diagnostic Histopathology, 2012, 18, 97-103.	0.4	25
27	Recent advances in breast cancer research impacting clinical diagnostic practice. Journal of Pathology, 2019, 247, 552-562.	4.5	24
28	Proteomic Analysis of the Breast Cancer Brain Metastasis Microenvironment. International Journal of Molecular Sciences, 2019, 20, 2524.	4.1	22
29	Accelerated wound healing phenotype in Interleukin 12/23 deficient mice. Journal of Inflammation, 2011, 8, 39.	3.4	21
30	Non-coding RNAs underlie genetic predisposition to breast cancer. Genome Biology, 2020, 21, 7.	8.8	21
31	The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence. British Journal of Cancer, 2021, 124, 156-160.	6.4	21
32	Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer. JCI Insight, 2019, 5, .	5.0	21
33	Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context. International Journal of Molecular Sciences, 2017, 18, 152.	4.1	20
34	â€~Omics Approaches in Breast Cancer Research and Clinical Practice. Advances in Anatomic Pathology, 2016, 23, 356-367.	4.3	17
35	Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases. International Journal of Molecular Sciences, 2019, 20, 1280.	4.1	17
36	Early activation of the interleukin-23-17 axis in a murine model of oropharyngeal candidiasis. Molecular Oral Microbiology, 2010, 25, 343-356.	2.7	16

Jodi Marie Saunus

#	Article	IF	CITATIONS
37	Identification and functional analysis of novel BRCA1 transcripts, including mouse Brca1-Iris and human pseudo-BRCA1. Breast Cancer Research and Treatment, 2010, 119, 239-247.	2.5	15
38	Molecular Aspects of Breast Cancer Metastasis to the Brain. Genetics Research International, 2011, 2011, 1-9.	2.0	14
39	The Brisbane Breast Bank. Open Journal of Bioresources, 2018, 5, .	1.5	13
40	Gene targeting demonstrates that inducible nitric oxide synthase is not essential for resistance to oral candidiasis in mice, or for killing of <i>Candida albicans</i> by macrophages <i>in vitro</i> . Oral Microbiology and Immunology, 2009, 24, 83-88.	2.8	11
41	Clinicopathologic significance of nuclear HER4 and phospho-YAP(S ¹²⁷) in human breast cancers and matching brain metastases. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094625.	3.2	11
42	Tradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer. Life Science Alliance, 2020, 3, e201900562.	2.8	11
43	Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer. Npj Breast Cancer, 2022, 8, 57.	5.2	11
44	Regulation ofBRCA1messenger RNA stability in human epithelial cell lines and during cell cycle progression. FEBS Letters, 2007, 581, 3435-3442.	2.8	9
45	N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease. BMC Cancer, 2022, 22, 334.	2.6	7
46	Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases. Biology, 2021, 10, 425.	2.8	6
47	Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient. Breast Cancer Research and Treatment, 2018, 170, 179-188.	2.5	5
48	Altered Calcium Influx Pathways in Cancer-Associated Fibroblasts. Biomedicines, 2021, 9, 680.	3.2	4
49	Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases. Cancers, 2022, 14, 533.	3.7	4
50	Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor–Positive Breast Cancer. JAMA Network Open, 2020, 3, e209486.	5.9	2
51	Breast Cancer Heterogeneity in Primary and Metastatic Disease. , 2013, , 65-95.		1
52	Emerging Biomarkers for Diagnosis, Prevention and Treatment of Brain Metastases—From Biology to Clinical Utility. Diseases (Basel, Switzerland), 2022, 10, 11.	2.5	1
53	Abstract LB-116: Cep55, a master regulator of cytokinesis in breast cancer pathogenesis. , 2014, , .		0
54	Abstract 1980: Long-range regulation of HOTAIR identifies novel biomarkers of breast cancer outcome and suggests a role in genome instability. , 2016, , .		0

#	Article	IF	CITATIONS
55	Abstract LB-350: In vivo kinome screen reveals potential drivers of brain metastasis. , 2016, , .		0
56	Abstract 99: Remodeling of calcium influx pathways in models of cancer associated fibroblasts in breast cancer. , 2019, , .		0